share_log

Oppenheimer Reiterates Outperform on Perspective Therapeutics, Maintains $1.2 Price Target

Benzinga ·  Mar 19 09:02

Oppenheimer analyst Jeff Jones reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $1.2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment